Kronos Bio Inc (NASDAQ: KRON) stock jumped 4.72% on Friday to $1.11 against a previous-day closing price of $1.06. With 0.29 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.24 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.1300 whereas the lowest price it dropped to was $0.9901. The 52-week range on KRON shows that it touched its highest point at $2.84 and its lowest point at $0.73 during that stretch. It currently has a 1-year price target of $9.00. Beta for the stock currently stands at 1.67.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of KRON was up-trending over the past week, with a rise of 38.80%, but this was up by 24.72% over a month. Three-month performance dropped to -22.92% while six-month performance fell -41.27%. The stock lost -50.22% in the past year, while it has lost -31.48% so far this year. A look at the trailing 12-month EPS for KRON yields -2.08 with Next year EPS estimates of -2.05. For the next quarter, that number is -0.54. This implies an EPS growth rate of 13.08% for this year and 0.68% for next year.
Float and Shares Shorts:
At present, 56.97 million KRON shares are outstanding with a float of 38.69 million shares on hand for trading. On Oct 30, 2023, short shares totaled 2.72 million, which was 4.66% higher than short shares on Sep 28, 2023. In addition to Dr. Norbert W. Bischofberger Ph.D. as the firm’s President, CEO & Director, Mr. Joshua A. Kazam serves as its Co-Founder & Director.
Institutional Ownership:
Through their ownership of 56.54% of KRON’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 4.93% of KRON, in contrast to 30.67% held by mutual funds. Shares owned by individuals account for 19.61%. As the largest shareholder in KRON with 4.98% of the stake, BVF Partners LP holds 2,905,043 shares worth 2,905,043. A second-largest stockholder of KRON, Perceptive Advisors LLC, holds 1,752,745 shares, controlling over 3.01% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in KRON, holding 1,674,808 shares or 2.87% stake. With a 1.83% stake in KRON, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 1,065,154 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.95% of KRON stock, is the second-largest Mutual Fund holder. It holds 553,029 shares valued at 0.48 million. BlackRock Health Sciences Trust I holds 0.49% of the stake in KRON, owning 284,272 shares worth 0.25 million.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for KRON since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With KRON analysts setting a high price target of $11.00 and a low target of $7.00, the average target price over the next 12 months is $9.00. Based on these targets, KRON could surge 890.99% to reach the target high and rise by 530.63% to reach the target low. Reaching the average price target will result in a growth of 710.81% from current levels.
Summary of Insider Activity:
Insiders traded KRON stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 5 while that of sell transactions has risen to 8 over the past year. The total number of shares bought during that period was 546,045 while 80,334 shares were sold.
